Antigen-receptor gene-modified T cells for treatment of glioma

Adv Exp Med Biol. 2012;746:202-15. doi: 10.1007/978-1-4614-3146-6_16.


Immunological effector cells and molecules have been shown to access intracranial tumor sites despite the existence of blood brain barrier (BBB) or immunosuppressive mechanisms associated with brain tumors. Recent progress in T-cell biology and tumor immunology made possible to develop strategies of tumor-associated antigen-specific immunotherapeutic approaches such as vaccination with defined antigens and adoptive T-cell therapy with antigen-specific T cells including gene-modified T cells for the treatment of patients with brain tumors. An array of recent reports on the trials of active and passive immunotherapy for patients with brain tumors have documented safety and some preliminary clinical efficacy, although the ultimate judgment for clinical benefits awaits rigorous evaluation in trials of later phases. Nevertheless, treatment with lymphocytes that are engineered to express tumor-specific receptor genes is a promising immunotherapy against glioma, based on the significant efficacy reported in the trials for patients with other types of malignancy. Overcoming the relative difficulty to apply immunotherapeutic approach to intracranial region, current advances in the understanding of human tumor immunology and the gene-therapy methodology will address the development of effective immunotherapy of brain tumors.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms / genetics
  • Brain Neoplasms / immunology
  • Brain Neoplasms / therapy*
  • Genetic Therapy / methods
  • Glioma / genetics
  • Glioma / immunology
  • Glioma / therapy*
  • Humans
  • Immunotherapy, Adoptive / methods
  • Models, Genetic
  • Models, Immunological
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / immunology*
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / metabolism
  • T-Lymphocytes / transplantation


  • Receptors, Antigen, T-Cell